JNJ — Johnson & Johnson Share Price
Last trade - 00:00- $379.41bn
- $392.88bn
- $88.82bn
- 95
- 52
- 88
- 93
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 14.45 | ||
| PEG Ratio (f) | 1.16 | ||
| EPS Growth (f) | 14.21% | ||
| Dividend Yield (f) | 3.4% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.86 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 18.63 | ||
| Price to Sales | 4.25 | ||
| EV to EBITDA | 11.66 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 19.45% | ||
| Return on Equity | 29.7% | ||
| Operating Margin | 29.78% | ||
Financial Summary
| Year End 29th Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 82,584 | 78,740 | 79,990 | 85,159 | 88,821 | 91,458.63 | 95,267.74 | 1.6% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -3.26 | +2.15 | +2.14 | +14.33 | -0.04 | +27.63 | +4.94 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company's primary focus is products related to human health and well-being. The Company operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolism. Medicines in this segment are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the orthopedic, surgery, cardiovascular, and vision fields. These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eyecare professionals, and clinics.
Directors
- Alex Gorsky CHM (60)
- Joaquin Duato CEO (59)
- Joseph Wolk CFO (54)
- Peter Fasolo CHO (58)
- Michael Ullmann EVP (62)
- Ashley Mcevoy EVP (50)
- Thibaut Mongon EVP (51)
- Michael Sneed EVP (61)
- Jennifer Taubert EVP (57)
- Kathryn Wengel EVP (55)
- Anne Mulcahy LED (68)
- Mary Beckerle IND (66)
- D. Scott Davis IND (69)
- Ian Davis IND (70)
- Jennifer Doudna IND (57)
- Marillyn Hewson IND (67)
- Hubert Joly IND (61)
- Mark Mcclellan IND (57)
- Charles Prince IND (71)
- A. Eugene Washington IND (70)
- Mark Weinberger IND (59)
- Nadja West IND (60)
- Ronald Williams IND (71)
- Last Annual
- December 29th, 2024
- Last Interim
- March 30th, 2025
- Incorporated
- November 10th, 1887
- Public Since
- September 25th, 1944
- No. of Shareholders
- 114,147
- No. of Employees
- 138,100
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- New York Stock Exchange
- Shares in Issue
- 2,406,073,279
- Address
- One Johnson & Johnson Plaza, NEW BRUNSWICK, 08933
- Web
- https://www.jnj.com/
- Phone
- +1 7325242455
- Contact
- Jessica Moore
- Auditors
- PricewaterhouseCoopers LLP
Latest News for JNJ
Upcoming Events for JNJ
Q2 2025 Johnson & Johnson Earnings Call
Q2 2025 Johnson & Johnson Earnings Release
Q3 2025 Johnson & Johnson Earnings Release
Similar to JNJ
Abbvie
New York Stock Exchange
Bausch Health Companies
New York Stock Exchange
Bristol-Myers Squibb Co
New York Stock Exchange
Bristol-Myers Squibb Co
New York Stock Exchange
Cardinal Health
New York Stock Exchange
FAQ
As of Today at 03:27 UTC, shares in Johnson & Johnson are trading at $157.69. This share price information is delayed by 15 minutes.
Shares in Johnson & Johnson last closed at $157.69 and the price had moved by +5.53% over the past 365 days. In terms of relative price strength the Johnson & Johnson share price has underperformed the S&P500 Index by -6.17% over the past year.
The overall consensus recommendation for Johnson & Johnson is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Johnson & Johnson dividend yield is 3.15% based on the trailing twelve month period.
Last year, Johnson & Johnson paid a total dividend of $4.96, and it currently has a trailing dividend yield of 3.15%. We do not have any data on when Johnson & Johnson is to next pay dividends.
We do not have data on when Johnson & Johnson is to next pay dividends. The historic dividend yield on Johnson & Johnson shares is currently 3.15%.
To buy shares in Johnson & Johnson you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $157.69, shares in Johnson & Johnson had a market capitalisation of $379.41bn.
Here are the trading details for Johnson & Johnson:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: JNJ
Based on an overall assessment of its quality, value and momentum Johnson & Johnson is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Johnson & Johnson is $170.13. That is 7.89% above the last closing price of $157.69.
Analysts covering Johnson & Johnson currently have a consensus Earnings Per Share (EPS) forecast of $10.63 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Johnson & Johnson. Over the past six months, its share price has outperformed the S&P500 Index by +3.15%.
As of the last closing price of $157.69, shares in Johnson & Johnson were trading +1.53% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Johnson & Johnson PE ratio based on its reported earnings over the past 12 months is 14.45. The shares last closed at $157.69.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Johnson & Johnson's management team is headed by:
- Alex Gorsky - CHM
- Joaquin Duato - CEO
- Joseph Wolk - CFO
- Peter Fasolo - CHO
- Michael Ullmann - EVP
- Ashley Mcevoy - EVP
- Thibaut Mongon - EVP
- Michael Sneed - EVP
- Jennifer Taubert - EVP
- Kathryn Wengel - EVP
- Anne Mulcahy - LED
- Mary Beckerle - IND
- D. Scott Davis - IND
- Ian Davis - IND
- Jennifer Doudna - IND
- Marillyn Hewson - IND
- Hubert Joly - IND
- Mark Mcclellan - IND
- Charles Prince - IND
- A. Eugene Washington - IND
- Mark Weinberger - IND
- Nadja West - IND
- Ronald Williams - IND